ClinicalTrials.gg
RecruitingNCT07466498Updated Nov 2, 2026

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

A Phase 2 interventional study of Androgen Receptor Pathway Inhibitor and Transdermal Estrogen in Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma and Stage IVB Prostate Cancer AJCC v8, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Fred Hutchinson Cancer Center · Phase 2, Interventional, and Treatment

How we know

Updated Nov 2, 2026Now RecruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Prostatic Neoplasms by Fred Hutchinson Cancer Center — 8 open to participants now, 8 under way, none of them phase 3. Prostatic Neoplasms · Fred Hutchinson Cancer Center.

Planned enrollment
4th of 13
60 · median 48
Started
2026
with 2 others
Phase 2
3 of 14
2 open now
Registered
11th of 14
by date

Among the 14 studies in Prostatic Neoplasms by Fred Hutchinson Cancer Center, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 2, and was the 11th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 14 studies in Prostatic Neoplasms by Fred Hutchinson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Prostatic Neoplasms by Fred Hutchinson Cancer Center, or all of them as a file.
02

Study summary

This phase II trial compares giving estrogen with an androgen receptor signaling inhibitor to standard of care luteinizing hormone-releasing hormone (LHRH) analogues with an androgen receptor signaling inhibitor for improving quality of life for patients with hormone sensitive prostate cancer that is newly diagnosed or that has come back after a period of improvement (recurrent) and has spread from where it first started (primary site) to other places in the body (metastatic). Standard prostate cancer treatment decreases hormone levels, specifically estrogen, in the body which can lead to hot flashes, fatigue, decreased bone health, and cardiovascular and metabolic dysfunction. Transdermal estrogen may help to alleviate these symptoms. Androgen receptor signaling inhibitors work by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. LHRH analogues are a type of androgen deprivation therapy that blocks the use of androgen by the tumor cells. Giving estrogen with androgen receptor signaling inhibitor may improve quality of life in men with newly diagnosed or recurrent metastatic hormone sensitive prostate cancer.

Read the detailed description

OUTLINE: Patients are randomized to 1 of 2 cohorts.

COHORT 1: Patients receive standard of care LHRH agonist or LHRH antagonist according to the Food and Drug Administration approved dose and schedule in the absence of disease progression or unacceptable toxicity. Starting 4 weeks after initiation of LHRH agonist/antagonist, patients also receive androgen receptor signaling inhibitor (ARSI) per physician's choice for a minimum of 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with a median daily hot flash score ≥ 6 after 12 weeks of therapy may crossover to cohort 2. Patients undergo computed tomography (CT) scan or magnetic resonance imaging (MRI), bone scan, dual x-ray absorptiometry (DEXA) scan and blood sample collection throughout the study.

COHORT 2: Patients receive estrogen via four transdermal patches twice weekly (BIW) on days 1, 4, 8, 12, 16, 20, 24 and 28 of cycle 1. Once castrate levels of testosterone are confirmed (\< 20 ng/dL), patients receive three patches BIW on days 1, 4, 8, 12, 16, 20, 24 and 28 of cycles thereafter. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients whose testosterone levels rise above castrate levels at any time while receiving three patches BIW then increase to four patches BIW. Starting 4 weeks after initiation of transdermal estrogen, patients also receive ARSI per physician's choice for a minimum of 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI, bone scan, DEXA scan and blood sample collection throughout the study.

After completion of study treatment, patients are followed up at 30 days and every 6 months for 2 years.

03

Conditions studied

  • Castration-Sensitive Prostate Adenocarcinoma
  • Metastatic Castration-Sensitive Prostate Adenocarcinoma
  • Stage IVB Prostate Cancer AJCC v8

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be willing to provide prior to any study specific procedures
  • Age ≥ 18 years
  • Documented confirmed adenocarcinoma of the prostate
  • Patients must have evidence of newly diagnosed or hormone sensitive prostate cancer on CT, positron emission tomography (PET), MRI or bone scan
  • No prior chemotherapy for the treatment of hormone sensitive prostate cancer
  • No prior therapy with an LHRH analogue or next-generation androgen receptor-signaling inhibitor (e.g. abiraterone, enzalutamide, etc.). Participants may have initiated on a first-generation androgen receptor (AR) antagonist (e.g. bicalutamide) prior to enrollment
  • ≥ 9 g/dL with no blood transfusion in the past 28 days (measured within 30 days prior to administration of study treatment)
  • count ≥ 100 x 10\^9/L (measured within 30 days prior to administration of study treatment)
  • (ANC) ≥ 1.5 x 10\^9/L (measured within 30 days prior to administration of study treatment)
  • (AST) or serum glutamic oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) or serum glutamic pyruvate transaminase (SGPT) ≤ 2.5 x institutional (measured within 30 days prior to administration of study treatment)
  • Patient must have estimated using the Cockcroft-Gault equation (measured within 30 days prior to administration of study treatment)
  • Total ≤ 1.5 x institutional upper limit of normal (ULN) with exception for Gilbert's syndrome (measured within 30 days prior to administration of study treatment)
  • (ECOG) performance status ≤ 2
  • Patients must have a ≥ 16 weeks
  • Patients must be willing and able to comply with protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
  • At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by CT, MRI and/or bone scan and is suitable for repeated assessment. Subjects without bone metastases must have per (RECIST) version (v) 1.1
  • Male patients and their partners, who are sexually active and of , must agree to the use of two highly effective forms of in combination, throughout the period of taking study treatment and for 6 months after last dose of study drug(s) to prevent pregnancy in a partner

Exclusion criteria

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study
  • Other unless curatively treated with no evidence of disease for ≥ 2 years. Exceptions include adequately treated non-melanoma skin cancer or non-muscle invasive bladder cancer
  • Patients with symptomatic uncontrolled . A scan to confirm the absence of brain metastases is not required. Patient with spinal cord compression unless considered to have received definitive therapy for this and evidence of clinically stable disease for 28 days
  • Patients considered inappropriate to receive docetaxel chemotherapy by their treating provider
  • Use of at a dose equivalent to > 10 mg of prednisone daily
  • Planning to receive concurrent treatment with another systemic cancer therapy, aside from an LHRH analogue
  • Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
  • Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, uncontrolled hypertension (blood pressure [BP] ≥ 165/100), unstable spinal cord compression, superior vena cava syndrome or extensive interstitial lung disease
  • Patients with a known to transdermal estradiol, LHRH analogue, ARSIs or any of the of these products
  • Patients with known active hepatitis (i.e., or C) due to risk of transmitting the infection through body or other body fluids
  • History of deep vein thrombosis, pulmonary embolism, myocardial infarction, angina, stroke or within 5 years of enrollment to the study
  • Known history of protein C, protein S, antithrombin deficiency or other known thrombophilic disorders
  • History of breast cancer
  • History of viral hepatitis unless treated with curative intent and with a documented negative viral load
  • History of systemic lupus erythematosus
  • Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of to participate in this study
  • Any psychological, familial, sociological or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule
  • Evidence of a pre-existing condition that, in the opinion of the investigator, would put the patient at risk from estradiol therapy.

    • Some examples include: history of blood clotting disorder, migraines with aura or other focal neurological symptom, angina ( grade III or higher)
  • Prior history of deep venous thrombosis or pulmonary embolism within 5 years prior to enrollment in the study and not currently on systemic anticoagulation

    • Excluded due to risk of venous thromboembolism from hormone supplementation
  • Patients with New York Heart Association (NYHA) class III or IV heart failure or history of a prior myocardial infarction (MI) or cerebrovascular accident (stroke or transient ischemic attack) within 5 years of enrollment to the study

    • Excluded due to increased risk of cardiovascular events with estradiol supplementation
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Cohort 1 (LHRH agonist/antagonist and ARSI)

    Patients receive standard of care LHRH agonist or LHRH antagonist according to the Food and Drug Administration approved dose and schedule in the absence of disease progression or unacceptable toxicity. Starting 4 weeks after initiation of LHRH agonist/antagonist, patients also receive ARSI per physician's choice for a minimum of 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with a median daily hot flash score ≥ 6 after 12 weeks of therapy may crossover to cohort 2. Patients undergo CT scan or MRI, bone scan, DEXA scan and blood sample collection throughout the study.

    Drug: Androgen Receptor Pathway Inhibitor · Procedure: Bone Scan · Procedure: Computed Tomography · Procedure: Dual X-ray Absorptiometry · Biological: Gonadotropin-releasing Hormone Analog · Procedure: Magnetic Resonance Imaging · Other: Survey Administration · Procedure: Biospecimen Collection

  • Experimental
    Cohort 2 (Estrogen and ARSI)

    Patients receive estrogen via four transdermal patches BIW on days 1, 4, 8, 12, 16, 20, 24 and 28 of cycle 1. Once castrate levels of testosterone are confirmed (\< 20 ng/dL), patients receive three patches BIW on days 1, 4, 8, 12, 16, 20, 24 and 28 of cycles thereafter. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients whose testosterone levels rise above castrate levels at any time while receiving three patches BIW then increase to four patches BIW. Starting 4 weeks after initiation of transdermal estrogen, patients also receive ARSI per physician's choice for a minimum of 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI, bone scan, DEXA scan and blood sample collection throughout the study.

    Drug: Androgen Receptor Pathway Inhibitor · Drug: Transdermal Estrogen · Procedure: Bone Scan · Procedure: Computed Tomography · Procedure: Dual X-ray Absorptiometry · Procedure: Magnetic Resonance Imaging · Other: Survey Administration · Procedure: Biospecimen Collection

Interventions

  • DrugAndrogen Receptor Pathway Inhibitor

    Given per standard of care

    Also known as: Androgen Receptor Signaling Inhibitor, AR Pathway Inhibitor, AR Signaling Inhibitor, AR Signaling Pathway Inhibitor, ARPI, ARSI

  • Given via transdermal patch

    Also known as: Divigel, Estrodiol Gel, EstroGel

  • ProcedureBone Scan

    Undergo bone scan

    Also known as: Bone Scintigraphy

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureDual X-ray Absorptiometry

    Undergo DEXA scan

    Also known as: BMD scan, bone mineral density scan, DEXA, DEXA (Bone Density), DEXA Scan, dual energy x-ray absorptiometric scan, Dual Energy X-ray Absorptiometry, Dual X-Ray Absorptometry, DXA, DXA SCAN

  • Given per standard of care

    Also known as: GnRH Agonist, GnRH Analog, Gonadotropin-Releasing Hormone Agonist, Gonadotropin-Releasing Hormone Analogue, LH-RH agonist, LH-RH Analogs, LHRH Agonist, luteinizing hormone-releasing hormone agonist, Luteinizing Hormone-Releasing Hormone Analog

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • OtherSurvey Administration

    Ancillary studies

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

06

What researchers measure

Primary outcomes

  1. Change in mean daily hot flash score

    As measured by Mayo Clinic Hot Flash Daily score. Will determine the analysis end time as the final dose of the study drug or 12 weeks whichever occurs first (efficacy analysis) or the 12-week dose (effectiveness analysis). Will then calculate the difference between the first hot flash score after the analysis end time and the baseline hot flash score for each patient, and then use difference-in-difference analysis to compare the mean changes between cohorts 1 and 2 using a two-sample t-test.

    Time frame: From baseline to a minimum of 12 weeks combination therapy

Secondary outcomes

  1. Change in quality of life (QOL) domains

    Assessed via patient-reported outcome measure questionnaires. Average change in QOL scores (total and for each domain) for each questionnaire will be calculated at each timepoint. A paired t-test will be used to assess for statistically significant changes in QOL from baseline to subsequent timepoints and linear mixed effects models will be used to evaluate trends over all timepoints.

    Time frame: From baseline to end of study visit, up to 2 years

  2. Bone mineral density

    Assessed from change in T-score (or Z-score) via dual energy x-ray absorptiometry.

    Time frame: From baseline to end of study visit, up to 2 years

  3. Changes in metabolic parameters: Mean change in hemoglobin A1c

    Assessed via results of hemoglobin A1c.

    Time frame: From baseline to end of study visit, up to 2 years

  4. Changes in metabolic parameters: Mean change in lipid panel values

    Assessed via results of lipid panel \[total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides\].

    Time frame: From baseline to end of study visit, up to 2 years

  5. Changes in sleep patterns and sleep quality

    Assessed via results of sleep questionnaire in combination with results of wearable sleep device to measure total sleep time, sleep onset latency and sleep efficiency.

    Time frame: From cycle 1 to end of study visit, up to 2 years

  6. Incidence of adverse events

    Assessed according to Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 2 years

  7. Time to radiographic progression

    Assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (soft tissue metastases) and Prostate Cancer Working Group 3 criteria (bone metastases).

    Time frame: From randomization to radiographic progression, up to 2 years

  8. Time to prostate specific antigen (PSA) progression

    Based on Prostate Cancer Working Group 3 criteria.

    Time frame: From randomization to PSA progression, up to 2 years

  9. Changes in immune cell composition

    Change in neutrophil to lymphocyte ratio.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Fred Hutch/University of Washington Cancer Consortium
    Seattle, Washington 98109, United States
    Recruiting
    • Michael Schweizer, MD · Contactschweize@uw.edu · 206-606-6252
    • Michael Schweizer, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2029, 30 months later.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 30 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Dec 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Mar 12, 2026
StartEst.
Dec 1, 2026was Nov 2026
Primary completionEst.
Jun 1, 2029
CompletionEst.
Jun 1, 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
Fred Hutch/University of Washington Cancer Consortium is now Recruiting
Oct 16, 2026
Start date
Nov 1, 2026→Dec 1, 2026
Nov 2, 2026
Eligibility
5 exclusion criteria added
What changed in the criteria
Exclusion criteria
  • AddedHistory of deep vein thrombosis, pulmonary embolism, myocardial infarction, angina, stroke or transient ischemic attack within 5 years of enrollment to the study
  • AddedKnown history of protein C, protein S, antithrombin deficiency or other known thrombophilic disorders
  • AddedHistory of breast cancer
  • AddedHistory of viral hepatitis unless treated with curative intent and with a documented negative viral load
  • AddedHistory of systemic lupus erythematosus
Nov 2, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in medianmean daily hot flash scoreTime frame: From baseline to a minimum of 12 weeks combination therapy
Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Start date Nov 1, 2026→Dec 1, 2026
    Eligibility 5 exclusion criteria added
    What changed in the criteria
    Exclusion criteria
    • AddedHistory of deep vein thrombosis, pulmonary embolism, myocardial infarction, angina, stroke or transient ischemic attack within 5 years of enrollment to the study
    • AddedKnown history of protein C, protein S, antithrombin deficiency or other known thrombophilic disorders
    • AddedHistory of breast cancer
    • AddedHistory of viral hepatitis unless treated with curative intent and with a documented negative viral load
    • AddedHistory of systemic lupus erythematosus
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in medianmean daily hot flash scoreTime frame: From baseline to a minimum of 12 weeks combination therapy
    + 3 other changes: verification date, description and arm descriptions
  2. Oct 16, 2026
    Not yet recruiting→Recruiting
    Fred Hutch/University of Washington Cancer Consortium is now Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07466498
Collaborators
Institute for Prostate Cancer Research (IPCR)
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 1, 2029 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Michael Schweizer, MD
Contact
schweize@uw.edu
206-606-6252
Michael Schweizer, MD
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Transdermal Estrogen

Start the discussion